MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Pro

What Do the SYNAPSE-CMT Phase 2a Results Mean for NMD Pharma

1 hour ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

What Do the JADE101 Phase 1 Interim Results Reveal

2 weeks ago

What Happened with aTyr Pharma's Initial Phase 3 Trial

1 months ago

What Do the Povorcitinib Trial Results Mean for Incyte

2 months ago

What Do UNFI's Mixed Q2 Results Really Mean for Investors

3 months ago

SYNAPSE-CMT Phase 2a Clinical Study Data Presented in Late-Breaking Oral Presentation at 2026 PNS Annual Meeting

NMD Pharma presented Phase 2a SYNAPSE-CMT data on ignaseclant for Charcot-Marie-Tooth disease at the 2026 PNS Annual Meeting. The late-breaking oral presentation covered safety and efficacy results fr...

CMT

Stock News•4 days ago

argenx Eyes More VYVGART Growth as Pipeline Catalysts Near

Argenx sees continued VYVGART growth in myasthenia gravis and CIDP, with multiple pipeline readouts expected in H2 2025.

ARGX

Stock News•1 week ago

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

TG Therapeutics reported 82% of MG patients achieved an MCID in MG-ADL with a mean >4 point improvement in a Phase 1 study of subcutaneous BRIUMVI (n=11), and initiated a potential registration-direct...

TGTX

Stock News•1 months ago

Entrada's Duchenne drug shown to improve muscle function in early trial

Entrada Therapeutics reported that its experimental drug improved a key measure of muscle function in children with Duchenne muscular dystrophy. These results stem from an early-to-mid stage clinical ...

TRDA